These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23000876)

  • 1. Cutaneous reactions to novel therapeutics.
    Hoang MP; Kroshinsky D
    Am J Dermatopathol; 2012 Oct; 34(7):679-87; quiz 688-90. PubMed ID: 23000876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib-induced skin eruption.
    Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
    Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
    Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
    Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed cross-reactivity between cyclophosphamide and chlorambucil.
    Ben Fredj N; Aouam K; Chaabane A; Njim L; Boughattas N
    J Clin Pharmacol; 2012 May; 52(5):771-4. PubMed ID: 21956606
    [No Abstract]   [Full Text] [Related]  

  • 5. Cutaneous drug eruptions induced by sorafenib: a case series.
    Maddox JS; Kung EF; Petronic-Rosic V; Sethi A
    J Drugs Dermatol; 2008 Sep; 7(9):891-3. PubMed ID: 19112807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
    Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
    Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the management of cutaneous toxicities of targeted therapies.
    Robert C; Sibaud V; Mateus C; Cherpelis BS
    Semin Oncol; 2012 Apr; 39(2):227-40. PubMed ID: 22484194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor causes a cutaneous eruption.
    Horn TD; Burke PJ; Karp JE; Hood AF
    Arch Dermatol; 1991 Jan; 127(1):49-52. PubMed ID: 1824746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a prominent granulomatous eruption after interferon-gamma therapy in a patient with mycosis fungoides.
    Haruyama S; Sugita K; Kawakami C; Nakamura M; Tokura Y
    Acta Derm Venereol; 2010 Mar; 90(2):190-1. PubMed ID: 20169308
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous drug eruptions associated with the use of new oncological drugs.
    Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R
    Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions.
    Curry JL; Torres-Cabala CA; Kim KB; Tetzlaff MT; Duvic M; Tsai KY; Hong DS; Prieto VG
    Int J Dermatol; 2014 Mar; 53(3):376-84. PubMed ID: 23879247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent erythema annulare centrifugum during ustekinumab treatment in a psoriatic patient.
    Chou WT; Tsai TF
    Acta Derm Venereol; 2013 Mar; 93(2):208-9. PubMed ID: 22983014
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute generalized exanthematous pustulosis due to etodolac in a patient with an iliopsoas muscle abscess.
    Nakamura Y; Takemoto A; Muto M
    Acta Derm Venereol; 2011 Sep; 91(5):589-90. PubMed ID: 21629972
    [No Abstract]   [Full Text] [Related]  

  • 14. New drug therapies and their effect on the skin.
    Treudler R
    J Dtsch Dermatol Ges; 2009 Jul; 7(7):623-37. PubMed ID: 19614812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-induced iatrogenic injury of skin: new drugs and new concepts.
    Choi JN
    Clin Dermatol; 2011; 29(6):587-601. PubMed ID: 22014981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin reactions to the new biologic anticancer drugs.
    Myskowski PL; Halpern AC
    Curr Opin Support Palliat Care; 2009 Dec; 3(4):294-9. PubMed ID: 19797958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-pigmenting fixed drug eruption induced by sorafenib.
    Tanabe K; Amoh Y; Mii S; Eto H; Iwamura M; Katsuoka K
    Acta Derm Venereol; 2010 May; 90(3):307. PubMed ID: 20526556
    [No Abstract]   [Full Text] [Related]  

  • 18. Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents: a relevant class-effect.
    Garcovich S; Burlando M; Rongioletti F; Garcovich A; Parodi A; Amerio P
    Acta Derm Venereol; 2010 May; 90(3):311-2. PubMed ID: 20526559
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
    Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
    Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
    Hammond-Thelin LA
    Dermatol Clin; 2008 Jan; 26(1):121-59, ix. PubMed ID: 18023775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.